Fig. 6: GNE-493 oral administration inhibits prostate cancer xenograft growth in nude mice.
From: GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms
The priCa-1 xenograft tumor-bearing nude mice were subject to daily oral administration of a single dose of GNE-493 (20 mg/kg body weights, 12 days) or the vehicle control (“Veh”); volumes of xenograft tumors (A) and the animal body weights (D) were recorded; the estimated daily tumor growth was calculated as well (B); the xenografts were all carefully isolated and weighted at Day-42 (C). At experimental Day-3 and experimental Day-9, one tumor from each group was isolated 6 h after initial GNE-493 or vehicle administration. In the tumor tissues listed proteins were examined (E and F). Total ceramide contents (G) and the relative TBAR activity (H) were examined as well. *P < 0.05 versus “Veh” group.
